Bharat Biotech International Limited

Quick facts

Phase 3 pipeline

• BBV154(Intranasal) & covaxin · Immunology / Infectious Disease
  BBV154 is an intranasal booster vaccine designed to enhance immune response against SARS-CoV-2 when administered after Covaxin (inactivated COVID-19 vaccine) priming.
• BBV154 Intranasal Vaccine · Immunology / Infectious Disease
  BBV154 is an intranasal recombinant vaccine that stimulates mucosal and systemic immune responses against SARS-CoV-2 by delivering viral antigens directly to respiratory tract tissues.
• Covishield · Other
• Hillchol vaccine · Cardiovascular
  Hillchol is a therapeutic vaccine designed to induce immune responses against cholesterol and lipid-related antigens to reduce cardiovascular risk.
• Intramuscular vaccine COVAXIN · Immunology / Infectious Disease
  COVAXIN is an inactivated whole-virus COVID-19 vaccine that stimulates immune responses against SARS-CoV-2 through presentation of viral antigens.
• ORV 116E · Immunology / Infectious Disease
  ORV 116E is an oral rotavirus vaccine candidate designed to provide immunization against rotavirus infection.
• ROTAVAC 5C -F1 · Immunology / Infectious Disease
  ROTAVAC 5C-F1 is a live attenuated rotavirus vaccine that stimulates immune responses against rotavirus to prevent gastroenteritis.
• ROTAVAC 5C -F2 · Infectious Diseases
  ROTAVAC 5C -F2 is a vaccine that protects against rotavirus infection.
• THR-100 · Infectious disease
  THR-100 is a recombinant human monoclonal antibody that targets the SARS-CoV-2 spike protein.

Phase 1 pipeline

• BBV152A - Phase I

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Bharat Biotech International Limited portfolio CI brief
• Bharat Biotech International Limited pipeline updates RSS

Frequently asked questions about Bharat Biotech International Limited

Related

• Sector hub: All tracked pharma companies